These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12626660)

  • 1. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3.
    Plotkin B; Kaidanovich O; Talior I; Eldar-Finkelman H
    J Pharmacol Exp Ther; 2003 Jun; 305(3):974-80. PubMed ID: 12626660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle.
    Kaidanovich-Beilin O; Eldar-Finkelman H
    J Pharmacol Exp Ther; 2006 Jan; 316(1):17-24. PubMed ID: 16169938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling.
    Sharfi H; Eldar-Finkelman H
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E307-15. PubMed ID: 18029441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats.
    Dokken BB; Henriksen EJ
    Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E207-13. PubMed ID: 16478771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3.
    Dokken BB; Saengsirisuwan V; Kim JS; Teachey MK; Henriksen EJ
    Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E615-21. PubMed ID: 18089761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus.
    Kaidanovich-Beilin O; Milman A; Weizman A; Pick CG; Eldar-Finkelman H
    Biol Psychiatry; 2004 Apr; 55(8):781-4. PubMed ID: 15050857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unlike insulin, amino acids stimulate p70S6K but not GSK-3 or glycogen synthase in human skeletal muscle.
    Liu Z; Wu Y; Nicklas EW; Jahn LA; Price WJ; Barrett EJ
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E523-8. PubMed ID: 14656717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide substrates suitable for assaying glycogen synthase kinase-3 in crude cell extracts.
    Welsh GI; Patel JC; Proud CG
    Anal Biochem; 1997 Jan; 244(1):16-21. PubMed ID: 9025901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.
    Cho H; Black SC; Looper D; Shi M; Kelly-Sullivan D; Timofeevski S; Siegel K; Yu XH; McDonnell SR; Chen P; Yie J; Ogilvie KM; Fraser J; Briscoe CP
    Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1142-51. PubMed ID: 18728225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraction activates glucose uptake and glycogen synthase normally in muscles from dexamethasone-treated rats.
    Ruzzin J; Jensen J
    Am J Physiol Endocrinol Metab; 2005 Aug; 289(2):E241-50. PubMed ID: 15741240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activity of glycogen synthase kinase-3beta: positive regulation of steady-state levels of insulin receptor substrates-1 and -2 in adrenal chromaffin cells.
    Nemoto T; Yokoo H; Satoh S; Yanagita T; Sugano T; Yoshikawa N; Maruta T; Kobayashi H; Wada A
    Brain Res; 2006 Sep; 1110(1):1-12. PubMed ID: 16870161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation and inactivation of glycogen synthase kinase-3 by soluble kit ligand in mouse oocytes during early follicular development.
    Liu L; Rajareddy S; Reddy P; Jagarlamudi K; Du C; Shen Y; Guo Y; Boman K; Lundin E; Ottander U; Selstam G; Liu K
    J Mol Endocrinol; 2007 Feb; 38(1-2):137-46. PubMed ID: 17242176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3.
    Lee S; Yang WK; Song JH; Ra YM; Jeong JH; Choe W; Kang I; Kim SS; Ha J
    Biochem Pharmacol; 2013 Apr; 85(7):965-76. PubMed ID: 23337568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice.
    Talior I; Yarkoni M; Bashan N; Eldar-Finkelman H
    Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E295-302. PubMed ID: 12857675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
    Ring DB; Johnson KW; Henriksen EJ; Nuss JM; Goff D; Kinnick TR; Ma ST; Reeder JW; Samuels I; Slabiak T; Wagman AS; Hammond ME; Harrison SD
    Diabetes; 2003 Mar; 52(3):588-95. PubMed ID: 12606497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
    Martinez A; Castro A; Dorronsoro I; Alonso M
    Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
    Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats.
    Cline GW; Johnson K; Regittnig W; Perret P; Tozzo E; Xiao L; Damico C; Shulman GI
    Diabetes; 2002 Oct; 51(10):2903-10. PubMed ID: 12351425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.